VYGR · Voyager Therapeutics, Inc.
$3.00
-0.04 (-1.32%)
At close · Jul 29
Market Cap
$183.68M
Shares
60.42M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.04
Open$3.10
Day$2.97–3.11
52W$2.88–5.55
Avg vol 30d728K
Short int3.8M · 6.4% float · 4.6d
Short vol61%
Last earningsNov 10, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−14%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−24%
trailing
YTD return
−23%
this year
Relative strength
−31%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
26 of 134 funds reported for Jun 30 · net -552.9K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.35% of float · ▲ +7.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
134 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+783%
Y/Y
EPS growth
−81%
Y/Y
Free cash flow
$-135.1M
Balance sheet
$65.3M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
26 of 134 funds reported for Jun 30 · net -552.9K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.35% of float · ▲ +7.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
134 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $3 · 6%
52-wk high $6
vs 200-day avg -23%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VYGR
this stock
Voyager Therapeutics, Inc.
|
$183.68M | -22.6% | +0.0% | — | 6.4% |
|
ONC
BeOne Medicines Ltd.
|
$474.96B | +8.8% | +22179.2% | 966.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VYGR | -0.3% | -15.3% | -24.0% | -13.1% | -22.7% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +0.7% | -15.3% | -31.4% | -12.4% | -31.3% |
Capital returns
Buyback program
· as of Dec 31, 2023
Authorized
—
Spent (derived)
—
Remaining
shares 131,470
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1640266
CUSIP
92915B106
13F (30d)
22 filings
22 filers
Visit website
Investor relations